|
10th Anniversary Conference Of The British HIV Association [BHIVA]15 – 17 April 2004, City Hall, Cardiff, UK |
[AUTHOR(S):] PA Cane1, G Dean2, M Fisher2, D Pao2, S Drake3, D Pillay1,4 and collaborating clinicians
1 Health Protection Agency Antiviral Susceptibility Reference Unit, Birmingham, 2 Royal Sussex Hospital, Brighton, 3 Birmingham Heartlands Hospital, 4University College London, UK
BHIVA Conf 2004 Apr 15-17;10:O7
AIM: To determine the stability of resistance-associated genotypic mutations observed in primary HIV Infection (PHI).
METHODS: 16 PHI patients with evidence of resistance-associated mutations were followed for up to 3 years
RESULTS: The persistence of resistance-associated mutations was variable. Y181C and K219Q in reverse transcriptase disappeared within 25 and 9 months, respectively, while K103N alone was stable for at least for 23 months in one patient. M41L, T69N and T215 variants were stable over the time periods studied up to 3 years, except for T215Y being replaced by T215C in one patient within 21 months. An additional patient was found to have virus showing M41L and T215S 10 years after seroconversion. Three-class resistance in three patients was found to be stable for up to 2 years and was associated with low viral loads, except for one patient showing a change from T215Y to T215C associated with a marked increase in the viral load.
CONCLUSIONS: Certain resistance-associated mutations are stable in the long term, and may be indicators of infection with drug-resistant virus. However, others may disappear rapidly, possibly as a result of fitness changes. Thus it would be better to undertake resistance testing at the time of diagnosis rather than waiting until treatment is indicated.
PRESENTING AUTHOR: D Pao
040415
O7
Copyright © 2004 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD